The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Exelixis; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
Lois Malizzia
No Relationships to Disclose
 
Karthik Devarajan
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb
 
Diana Luong
No Relationships to Disclose
 
Elizabeth Sullivan
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)